532523 and BIOCON Related Headlines

Go Back

Apr 21, 2026 07:05AM Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®

Apr 7, 2026 09:31AM Biocon launches denosumab biosimilars in US market

Apr 7, 2026 08:05AM Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars

Mar 27, 2026 07:00AM Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

Oct 1, 2025 07:30AM Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

532523 and BIOCON Related Press Releases

Go Back

Apr 21, 2026 07:05AM Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®

Apr 7, 2026 08:05AM Biocon Announces U.S. Commercial Launch of Bosaya™ and Aukelso™, Denosumab Biosimilars

Mar 27, 2026 07:00AM Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026

Oct 1, 2025 07:30AM Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

532523 and BIOCON Related SEC Filings

Go Back